Good Steward Wealth Advisors LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 51.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,799 shares of the biopharmaceutical company's stock after selling 2,926 shares during the period. Good Steward Wealth Advisors LLC's holdings in Gilead Sciences were worth $310,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $25,000. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Goodman Advisory Group LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares during the last quarter. Finally, Core Alternative Capital lifted its stake in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.
Analysts Set New Price Targets
Several brokerages have commented on GILD. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the company an "overweight" rating in a research note on Tuesday. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective for the company in a research note on Friday, July 25th. Rothschild & Co Redburn lifted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the company a "buy" rating in a research note on Friday, September 12th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $117.17.
View Our Latest Analysis on GILD
Insider Activity at Gilead Sciences
In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $978,880.80. The trade was a 35.92% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,390,030. 0.27% of the stock is owned by corporate insiders.
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded up $1.36 during trading hours on Thursday, reaching $113.62. 6,953,837 shares of the company's stock were exchanged, compared to its average volume of 8,068,932. Gilead Sciences, Inc. has a 1 year low of $81.83 and a 1 year high of $121.83. The company has a market capitalization of $140.98 billion, a P/E ratio of 22.63, a price-to-earnings-growth ratio of 0.75 and a beta of 0.36. The business has a fifty day moving average of $114.03 and a two-hundred day moving average of $110.08. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the prior year, the firm earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio is currently 62.95%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
